UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 16, 2026 |
AIRGAIN, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware | 001-37851 | 95-4523882 | ||
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||
|
|
|
|
|
3611 Valley Centre Drive Suite 150 |
| |||
San Diego, California |
| 92130 | ||
(Address of Principal Executive Offices) |
| (Zip Code) | ||
Registrant’s Telephone Number, Including Area Code: 760-579-0200 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
| Trading |
|
|
Common stock, par value $0.0001 per share |
| AIRG |
| Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 16, 2026, Airgain, Inc. (the “Company”) terminated the employment of Ali Sadri, Ph.D., the Company’s Chief Technology Officer, effective April 17, 2026. In connection with this change, the Company eliminated the Office of the CTO and reassigned certain resources to the product development team to support the planned accelerated commercialization of its growth platforms. Dr. Sadri will be eligible to receive severance benefits under his existing severance agreement, subject to his execution and non-revocation of a separation agreement containing a general release of claims and standard restrictive covenants. These benefits include: a lump sum cash payment of $325,000, representing 12 months of base salary; a lump sum cash payment of $57,164, representing his prorated target bonus for 2026; continued health coverage under COBRA at the Company’s expense for 12 months following his last day of employment; and vesting of all outstanding equity awards that otherwise would have vested during the 12 months following the effective date of termination.
The foregoing description of the separation agreement with Dr. Sadri is qualified in its entirety by reference to the separation agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
| AIRGAIN, INC. | ||
|
|
|
| |||
Date: April 21, 2026 |
|
|
|
|
| /s/ Michael Elbaz |
|
|
|
|
|
| Michael Elbaz Chief Financial Officer and Secretary |